Elanco Animal Health Incorporated Employee Count
The employee counts Elanco Animal Health Incorporated states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 9,400; Filing 2026-02-24; Lease expense per employee $7,765.96.
- 2024-12-31: Employees (as filed) 9,000; Filing 2025-02-25; Lease expense per employee $6,111.11.
- 2023-12-31: Employees (as filed) 9,300; Filing 2024-02-26; Lease expense per employee $5,053.76.
- 2022-12-31: Employees (as filed) 1,080; Filing 2023-03-01; Lease expense per employee $47,222.22.
- Available history
- 2018-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 9,400 full-time | 2026-02-24 | $7,765.96 total lease cost |
| 2024-12-31 | 9,000 full-time | 2025-02-25 | $6,111.11 total lease cost |
| 2023-12-31 | 9,300 full-time | 2024-02-26 | $5,053.76 total lease cost |
| 2022-12-31 | 1,080 | 2023-03-01 | $47,222.22 total lease cost |
| 2021-12-31 | 1,100 | 2022-02-28 | $43,636.36 total lease cost |
| 2020-12-31 | 1,200 | 2021-03-01 | $35,000.00 total lease cost |
| 2019-12-31 | 765 | 2020-02-28 | $37,908.50 total lease cost |
| 2018-12-31 | 690 | 2019-02-20 | $68,840.58 rent expense, net |
Headcount breakdown as filed
| Fiscal year end | Employees | Xbrl:DisposalGroupClassification | Xbrl:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperations | Xbrl:SubsequentEventType | Filing |
|---|---|---|---|---|---|
| 2025-12-31 | 9,400 full-time | DisposalGroupDisposedOfBySaleNotDiscontinuedOperations: 50 DisposalGroupDisposedOfBySaleNotDiscontinuedOperations: 280 | NewZealandManufacturingFacility: 50 AquaBusiness: 280 | 2026-02-24 “As of December 31, 2025, we employed approximately 9,400 full time employees and approximately 500 fixed-duration employees, which are individuals hired for a pre-defined length of time (typically one to four years).” | |
| 2024-12-31 | 9,000 full-time | DisposalGroupDisposedOfBySaleNotDiscontinuedOperations: 280 | AquaBusiness: 280 | 2025-02-25 “As of December 31, 2024, we employed approximately 9,000 full time employees and approximately 450 fixed-duration employees, which are individuals hired for a pre-defined length of time (typically one to four years).” | |
| 2023-12-31 | 9,300 full-time | DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperations: 600 DiscontinuedOperationsDisposedOfBySale: 280 | AquaBusiness: 280 | SubsequentEvent: 280 | 2024-02-26 “As of December 31, 2023, we employed approximately 9,300 full time employees and approximately 500 fixed-duration employees, which are individuals hired for a pre-defined length of time (typically one to four years).” |
| 2022-12-31 | 1,080 | DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperations: 600 | 2023-03-01 “As of December 31, 2022, we employed approximately 1,080 employees in our global R&D and Regulatory Affairs organizations.” | ||
| 2021-12-31 | 1,100 | DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperations: 600 | 2022-02-28 “As of December 31, 2021, we employed approximately 1,100 employees in our global R&D and Regulatory Affairs organizations.” |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |